Department of Neurological Surgery, University of California San Francisco, San Francisco, California, USA.
Department of Radiation Oncology, University of California San Francisco, San Francisco, California, USA.
Neuro Oncol. 2018 Apr 9;20(5):632-641. doi: 10.1093/neuonc/nox205.
Rare multicentric lower-grade gliomas (LGGs) represent a unique opportunity to study the heterogeneity among distinct tumor foci in a single patient and to infer their origins and parallel patterns of evolution.
In this study, we integrate clinical features, histology, and immunohistochemistry for 4 patients with multicentric LGG, arising both synchronously and metachronously. For 3 patients we analyze the phylogeny of the lesions using exome sequencing, including one case with a total of 8 samples from the 2 lesions.
One patient was diagnosed with multicentric isocitrate dehydrogenase 1 (IDH1) mutated diffuse astrocytomas harboring distinct IDH1 mutations, R132H and R132C; the latter mutation has been associated with Li-Fraumeni syndrome, which was subsequently confirmed in the patient's germline DNA and shown in additional cases with The Cancer Genome Atlas data. In another patient, phylogenetic analysis of synchronously arising grade II and grade III diffuse astrocytomas demonstrated a single shared mutation, IDH1 R132H, and revealed convergent evolution via non-overlapping mutations in ATRX and TP53. In 2 cases, there was divergent evolution of IDH1-mutated and 1p/19q-codeleted oligodendroglioma and IDH1-mutated and 1p/19q-intact diffuse astrocytoma, occurring synchronously in one case and metachronously in a second.
Each tumor in multicentric LGG cases may arise independently or may diverge very early in their development, presenting as genetically and histologically distinct tumors. Comprehensive sampling of these lesions can therefore significantly alter diagnosis and management. Additionally, somatic IDH1 R132C mutation in either multicentric or solitary LGG identifies unsuspected germline TP53 mutation, validating the limited number of published cases.
罕见的多中心低级别胶质瘤(LGG)代表了一个独特的机会,可以研究单个患者中不同肿瘤灶之间的异质性,并推断它们的起源和并行进化模式。
在这项研究中,我们整合了 4 名多中心 LGG 患者的临床特征、组织学和免疫组织化学,这些患者的肿瘤同时或先后发生。对于 3 名患者,我们使用外显子组测序分析病变的系统发育,其中 1 名患者共有 2 个病灶的 8 个样本。
1 名患者被诊断为多中心 IDH1 突变弥漫性星形细胞瘤,具有不同的 IDH1 突变,R132H 和 R132C;后者突变与 Li-Fraumeni 综合征有关,随后在患者的种系 DNA 中得到证实,并在具有癌症基因组图谱数据的其他病例中得到证实。在另 1 名患者中,同步发生的 2 级和 3 级弥漫性星形细胞瘤的系统发育分析显示了 1 个共同的突变 IDH1 R132H,并通过 ATRX 和 TP53 的非重叠突变揭示了趋同进化。在 2 例病例中,IDH1 突变和 1p/19q 缺失的少突胶质细胞瘤和 IDH1 突变和 1p/19q 完整的弥漫性星形细胞瘤发生了分歧进化,1 例同步发生,另 1 例先后发生。
多中心 LGG 病例中的每个肿瘤可能独立发生,也可能在其发育早期就发生分歧,表现为遗传和组织学上明显不同的肿瘤。因此,对这些病变进行全面采样可以显著改变诊断和治疗。此外,多中心或孤立性 LGG 中的体细胞 IDH1 R132C 突变可识别出未被怀疑的种系 TP53 突变,验证了少数已发表的病例。